Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | GLA | P06280 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | ALPL | P05186 | 1/20 | 0.41 |
| ▸ | ALPG | P10696 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3744031 | 1.00 | CYP3A4 (0.53) | CYP3A4CYP2C9TRPM8NPC1LMNA | |
| SCHEMBL2770423 | 0.89 | CYP3A4 (0.53) | CYP3A4CYP2C9TRPM8NPC1LMNA | |
| SCHEMBL3745551 | 0.89 | CYP3A4 (0.53) | CYP3A4CYP2C9TRPM8NPC1LMNA | |
| SCHEMBL3753378 | 0.88 | CYP3A4 (0.48) | CYP3A4CYP2C9TRPM8NPC1LMNA | |
| SCHEMBL2773647 | 0.88 | CYP3A4 (0.48) | CYP3A4CYP2C9TRPM8NPC1LMNA | |
| SCHEMBL3742883 | 0.86 | CYP3A4 (0.48) | CYP3A4CYP2C9TRPM8KDM4EALDH1A1 | |
| SCHEMBL2774398 | 0.86 | CYP3A4 (0.48) | CYP3A4CYP2C9TRPM8KDM4EALDH1A1 | |
| SCHEMBL2772611 | 0.81 | CYP3A4 (0.54) | CYP3A4CYP2C9TRPM8TRPV1IKBKB | |
| SCHEMBL3755085 | 0.81 | CYP3A4 (0.54) | CYP3A4CYP2C9TRPM8TRPV1IKBKB | |
| SCHEMBL3751842 | 0.80 | CYP3A4 (0.57) | CYP3A4CYP2C9TRPM8NPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217060-B2 | Benzimidazole derivatives useful as TRP M8 receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2012-07-10 | — | — | US | claimed |
| WO-2010132247-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRP M8 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | WO | claimed |
| US-20100292276-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRP M8 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2010-11-18 | — | — | US | claimed |
| US-8217060-B2 | Benzimidazole derivatives useful as TRP M8 receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2012-07-10 | — | — | US | disclosed |
| WO-2010132247-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRP M8 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292276-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRP M8 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292276-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRP M8 RECEPTOR MODULATORS | TRPM8, TRPV1, TRPA1 | CYP3A4 2735/4885CYP2C9 2805/4885TRPM8 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.